Heart Protection Study Group J Vasc Surg 2007;45:645-54

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD)

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Effects of simvastatin allocation on first major coronary event, stroke, or revascularization in participants

presenting with or without peripheral artery disease

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Absolute effects of simvastatin allocation on 5-year rates of first major vascular events among participants subdivided by prior PAD

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Effects of simvastatin allocation on major vascular events in prior disease subgroups

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Effects of simvastatin allocation on first major vascular event in participants with or without PAD subdivided by other presenting features

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Effects of simvastatin allocation on first and all major vascular events in participants with or without PAD

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Effects of simvastatin allocation on first peripheral vascular event subdivided by presenting features

Heart Protection Study Group J Vasc Surg 2007;45:645-54

Average use of statin (study or non-study), and average plasma LDL cholesterol concentrations, during follow-up. Table online only

Heart Protection Study Group J Vasc Surg 2007;45:645-54

DISCUSSION

Heart Protection Study Group J Vasc Surg 2007;45:645-54

INVITED COMMENTARYWilliam R. Hiatt

Heart Protection Study Group J Vasc Surg 2007;45:645-54